579 related articles for article (PubMed ID: 14658007)
1. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
[TBL] [Abstract][Full Text] [Related]
4. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
5. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
Bocci G; Falcone A; Fioravanti A; Orlandi P; Di Paolo A; Fanelli G; Viacava P; Naccarato AG; Kerbel RS; Danesi R; Del Tacca M; Allegrini G
Br J Cancer; 2008 May; 98(10):1619-29. PubMed ID: 18443598
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
8. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
[TBL] [Abstract][Full Text] [Related]
9. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
Gliniak B; Le T
Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
15. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Kumazawa E; Jimbo T; Ochi Y; Tohgo A
Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
[TBL] [Abstract][Full Text] [Related]
16. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
[TBL] [Abstract][Full Text] [Related]
18. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR; Grivicich I; Peters GJ; Schwartsmann G
Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
[TBL] [Abstract][Full Text] [Related]
19. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
Bruns CJ; Shinohara H; Harbison MT; Davis DW; Nelkin G; Killion JJ; McConkey DJ; Dong Z; Fidler IJ
Cancer Res; 2000 Jan; 60(1):2-7. PubMed ID: 10646841
[TBL] [Abstract][Full Text] [Related]
20. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
